All Articles

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations.

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease.

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation.

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums.

Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study.

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment.

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and MET^Amp/Ex14Δ.

Dual treatment with ramucirumab and erlotinib produced similar results in patients with ex21 and ex19 mutations.

This study reports on the ZENITH20-2 cohort of previously treated patients with advanced NSCLC and an HER2 exon 20 insertion mutation.

Savolitinib had promising antitumor activity in patients with METex14+ NSCLC and showed acceptable tolerability.